Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II trial of IPH 2201 monotherapy in patients with metastatic or recurrent platinum refractory squamous cell carcinoma of the head and neck.

Trial Profile

Phase II trial of IPH 2201 monotherapy in patients with metastatic or recurrent platinum refractory squamous cell carcinoma of the head and neck.

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Feb 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Monalizumab (Primary)
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Sponsors Innate Pharma
  • Most Recent Events

    • 19 Feb 2015 According to Innate Pharma media release, first patient in this trial was treated in December 2014.
    • 19 Feb 2015 According to Innate Pharma media release, status changed from not yet recruiting to recruiting.
    • 17 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top